RxDoctor Payments Data

Grettel Rodriguez Garcia

Obesity Medicine · Vero Beach, FLNPI 1063836005

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Lilly USA, LLC at 26.4% of the total.

$553in general payments, 2019–2025

Across 20 payments — averaging $27.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$146
  • Novo Nordisk$106
  • Currax Pharmaceuticals LLC$105
  • Edwards Lifesciences$92
  • Kvk-tech, Inc.$52
  • Boston Scientific$22
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC2$146
Novo Nordisk6$106
Currax Pharmaceuticals LLC7$105
Edwards Lifesciences1$92
Kvk-tech, Inc.1$52
Boston Scientific1$22
Nalpropion Pharmaceuticals LLC1$16
AbbVie1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$553 in reported general payments places this provider in the 70th percentile of 21 obesity medicine providers in Florida.

See all obesity medicine providers in Florida

Medicare billing

Part B allowed, 2024
$68,265
Medicare patients
202
Services billed
1,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide271$311,950
MounjaroTirzepatide91$116,886
WegovySemaglutide16$20,567
RybelsusSemaglutide17$17,363
LinzessLinaclotide18$16,573
Bupropion XlBupropion Hcl128$2,013
Naltrexone Hcl51$1,344
Topiramate110$582
Atorvastatin Calcium40$417
Levothyroxine Sodium29$401
Gabapentin11$318
Amlodipine Besylate33$308
Metoprolol Succinate25$303
Simvastatin18$285
Metformin Hcl78$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$106$349,880304 claims
Lilly USA, LLCMounjaro$146$116,88691 claims
AbbVieLinzess$13$16,57318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 21 obesity medicine providers in Florida.

Other obesity medicine in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →